Boehringer Ingelheim and Zealand Pharma are presenting full Phase III SYNCHRONIZE-1 data on survodutide, their glucagon/GLP-1 dual agonist: 16.6% average weight loss at 76 weeks versus 3.2% on placebo
10.3389/fphys.2016.00233 147
Az alvshiny azonban tartsan alacsony GSH-szintet eredmnyezhet
It brings together reduced glutathione (Luthione, 1200mg), alpha-lipoic acid (Cindella, also called thioctic acid) and high-dose vitamin C (DHNP ascorbic acid)
Rare but serious side effects (still worth knowing): Pancreatitis (very rare, but serious) Thyroid issues , especially if you have a personal or family history Gallbladder discomfort in some women, particularly with higher doses Pro tip : If you have a sensitive stomach, microdosing might actually be a gentler way to introduce GLP-1s without overwhelming your system
Never Share a Liraglutide Injection Pen Between Patients Advise patients that they must never share a liraglutide injection pen with another person, even if the needle is changed, because doing so carries a risk for transmission of blood-borne pathogens [see Warnings and Precautions (5.3)]
